Why the study?
Does chemotherapy add survival benefit to metastasectomy in patients with recurrent osteosarcoma presenting as a single pulmonary metastasis more than 1 year after diagnosis?
Does chemotherapy add survival benefit to metastasectomy in patients with recurrent osteosarcoma presenting as a single pulmonary metastasis more than 1 year after diagnosis?
Metastasectomy is the primary treatment for recurrent osteosarcoma with a single late pulmonary metastasis, yielding long-term survival in about half of patients, with no added benefit from chemotherapy.
Approximately half of the patients with recurrent osteosarcoma presenting as a single pulmonary metastasis more than 1 year after diagnosis were long-term survivors. Metastasectomy was the primary treatment; chemotherapy did not add benefit.
No takes yet. Share an insight, caveat, or question.
Daw et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: